Evaluation of therapeutic safety and efficacy of tranexamic acid or aprotinin in absolute blood loss and transfusion in pediatric patients undergoing craniosynostosis surgery

Tehran University of Medical Sciences0 个研究点目标入组 90 人开始时间: 待定最近更新: 2020年7月13日

试验速览

暂无简介。

•?Age between 2 months and 2 years, both sex
•?Single or multi-suture craniosynostosis including metopic, sagittal, unicoronal, and bicoronal synostoses
•?Syndromic or non-syndromic craniosynostosis
•?Hemoglobin level of equal or more than 13 mg/dl
•?Patient’s parents or legal guardian agreement to sign the informed consent form

•?Indication for endoscopic craniosynostosis surgery
•?History of coagulopathies or hemoglobinopathies in patient or first degree family (hemophilia, abnormal PT, PTT, INR tests, afibrinogenemia, congenital coagulatory factor deficiencies)
•?Craniofacial surgeries
•?Craniosynostosis recurrence
•?Secondary craniosynostosis
•?Abnormal renal function tests including abnormal BUN and Cr for age or family history of hereditary renal disease as polycystic kidney
•?Allergy to Aprotinin, tested 30 minutes pre operation with 0.1 dose of therapeutic dose
•?Congenital heart disease

发起方